British drugmaker AstraZeneca has completed an agreement for the global licence to tralokinumab in skin diseases with dermatology care specialist LEO Pharma.
Last month, AstraZeneca announced it had entered into an agreement with LEO for the development and commercialisation of tralokinumab for atopic dermatitis.
AstraZeneca global product and portfolio strategy executive vice-president Luke Miels said: “This agreement allows us to concentrate our efforts on tralokinumab’s potential for patients with severe asthma, a priority area for AstraZeneca, while benefitting from LEO Pharma’s expertise in dermatology for the continued development and commercialisation of tralokinumab in atopic dermatitis and other dermatology conditions.”
The agreement is expected to support AstraZeneca in maintaining a sharper focus on main therapy areas.
The licencing deal for Tralokinumab is an anti-interleukin-13 (IL-13) monoclonal antibody and is expected to generate more than $1bn in commercially related milestones and up to mid-teen tiered percentage royalties on product sales for AstraZeneca.
Tralokinumab has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
It is also in Phase III development for patients with severe asthma.
Under the agreement, LEO Pharma made an upfront payment to AstraZeneca of $115m for the exclusive global rights to tralokinumab in atopic dermatitis and any future additional dermatology indications.
AstraZeneca will manufacture and supply tralokinumab to LEO Pharma and retain all rights to tralokinumab in respiratory disease and any other indications outside of dermatology.
In a separate development, AstraZeneca entered into an agreement with LEO for the exclusive licence to brodalumab in Europe.
IL-17 receptor monoclonal antibody Brodalumab is under regulatory review for patients with moderate-to-severe plaque psoriasis.